Female mice exhibit resistance to disease progression despite early pathology in a transgenic mouse model inoculated with alpha-synuclein fibrils
Open Access
- 22 February 2025
- journal article
- research article
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1-14
Abstract
Despite known sex differences in human synucleinopathies such as Parkinson’s disease, the impact of sex on alpha-synuclein pathology in mouse models has been largely overlooked. To address this need, we examine sex differences in whole brain signatures of neurodegeneration due to aSyn toxicity in the M83 mouse model using longitudinal magnetic resonance imaging (MRI; T1-weighted; 100 μm3 isotropic voxel; -7, 30, 90 and 120 days post-injection [dpi]; n ≥ 8 mice/group/sex/time point). To initiate aSyn spreading, M83 mice are inoculated with recombinant human aSyn preformed fibrils (Hu-PFF) or phosphate buffered saline in the right striatum. We observe more aggressive neurodegenerative profiles over time for male Hu-PFF-injected mice when examining voxel-wise trajectories. However, at 90 dpi, we observe widespread patterns of neurodegeneration in the female Hu-PFF-injected mice. These differences are not accompanied by any differences in motor symptom onset between the sexes. However, male Hu-PFF-injected mice reached their humane endpoint sooner. These findings suggest that post-motor symptom onset, despite accelerated disease trajectories for male Hu-PFF-injected mice, neurodegeneration may appear sooner in the female Hu-PFF-injected mice (prior to motor symptomatology). These findings suggest that sex-specific synucleinopathy phenotypes urgently need to be considered to improve our understanding of neuroprotective and neurodegenerative mechanisms.Keywords
All Related Versions
Funding Information
- Santé
- Healthy Brains, Healthy Lives
- Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada
- Gouvernement du Canada | Canadian Institutes of Health Research
- Healthy Brains, Healthy Lives TRanslational Initiative to DE-risk NeuroTherapeutics (TRIDENT) James McGill
This publication has 97 references indexed in Scilit:
- Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body DiseaseJournal of Biological Chemistry, 2006
- Statistical validation of image segmentation quality based on a spatial overlap index1Academic Radiology, 2004
- Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonismNeurology, 2003
- Staging of brain pathology related to sporadic Parkinson’s diseaseNeurobiology of Aging, 2003
- Deformation-based surface morphometry applied to gray matter deformationNeuroImage, 2003
- Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-SynucleinNeuron, 2002
- α-Synuclein is phosphorylated in synucleinopathy lesionsNature Cell Biology, 2002
- α-Synuclein in Lewy bodiesNature, 1997
- Mutation in the α-Synuclein Gene Identified in Families with Parkinson's DiseaseScience, 1997
- Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletionJournal of Neuroscience Methods, 1997